Novo Nordisk Now Goes by Just Novo, and Even Its Bull Turned Around
The Wegovy maker is shortening its everyday name as it fights to win back ground from Eli Lilly. The legal name stays put, and the comeback plan’s next phase is expected at an investor update later this month.
By Sean Anees Saifi · Capital Wealth · Published Tuesday, September 15, 2026 · Source: The Wall Street Journal, September 15, 2026 edition (Business & Finance)
Key Points
Novo Nordisk (NVO) will go by Novo — Latin for new — in day-to-day operations, but keeps Novo Nordisk as its legal name.
Its refreshed logo keeps the Apis bull of ancient Egypt, part of the brand for more than a century — now facing right, not left.
Since taking over in August 2025, CEO Mike Doustdar has pushed through 9,000 job cuts and launched a pill version of Wegovy.
The Wegovy pill, which put Novo ahead of Eli Lilly (LLY) in oral weight-loss drugs, has topped five million prescriptions since its January launch.
Some investors worry about the pipeline after disappointing CagriSema data; Doustdar is expected to detail the next phase of his comeback later this month.
9,000
job cuts under CEO Mike Doustdar
5M+
Wegovy pill prescriptions since its January launch
1989
merger that created the Novo Nordisk name
The new name and the right-facing bull are the easy part. The next phase of Novo’s comeback plan is expected at an investor update later this month.
In one line: Novo Nordisk is going by Novo day to day, but for shareholders the pill’s momentum, the pipeline and this month’s investor update matter more than the logo.
Novo Nordisk (NVO), the Danish drugmaker behind Wegovy, would like to be called Novo now. Same company, fewer letters, and a bull that’s turned around. The bet is that a shorter name lands better with consumers as Novo tries to win back ground from Eli Lilly (LLY), which took the weight-loss crown Novo pioneered. Novo is Latin for new. As hints go, it’s not subtle.
What actually changed
Less than you’d think. Novo is the everyday name, but Novo Nordisk stays the legal name worldwide. The longer name dates to a 1989 merger of two Danish companies with roots in the origins of insulin production in 1920s Scandinavia.
The logo keeps the Apis bull of ancient Egypt, a brand fixture for more than a century, but it now faces right instead of left. Ed Corbett, a brand strategist at consulting firm Branding Science, says Novo wants to signal “a change of direction” to its own staff as well as outsiders. He also says a new name isn’t a cure-all.
The consumer angle is no accident. Novo says it’ll push a more competitive culture for a faster, increasingly consumer-driven market. Some analysts say weight-loss pills resemble consumer-health products more than conventional prescription medicines.
The part that isn’t cosmetic
Doustdar has run the company since August 2025. His cost-savings plan included 9,000 job cuts and a pill version of Wegovy, which put Novo ahead of Lilly in oral weight-loss drugs. Last month, citing the pill’s more than five million prescriptions since January, Novo raised its full-year sales and operating-profit guidance — its own forecast for the year.
The worry is what comes next. Some investors are uneasy about the pipeline — the drugs still in development — after disappointing results for CagriSema, a next-generation weight-loss and diabetes drug, and for an experimental cardiovascular drug. Doustdar is expected to lay out the next phase of his comeback at an investor update later this month. That meeting should say more than any logo.
What It Means For Your Portfolio
Hold — judge the business, not the badge
When a company you own rebrands, skip the logo reveal and read the guidance, the costs and the pipeline — that’s where the business lives.
A new name can mark a genuine reset, and it may here, but a signal isn’t a result. When a holding rebrands, ask the dull questions. Is it raising or cutting its own forecast? Are costs coming down? Did the latest product data disappoint? Those answers describe a business; logos just decorate it. General planning principles, not advice for anyone in particular.
Nothing in the Capital Wealth portfolios changes because of this story. We don’t own Novo or Lilly, our health-care holding is Amgen (AMGN), and nothing new gets bought before Wednesday’s Fed decision. The household move: when a company you own rebrands, reread its latest results before reacting. Umbrellas don’t need rebrands; they need to be within reach. Fifteen minutes and your statement will show whether yours is.
